Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Biocon announced the commercial launch of Yesafili™ (aflibercept-jbvf) in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation* by the U.S. Food and Drug Administration in May 2024, allowing substitution at the pharmacy level in accordance with state laws.
Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, “The launch of Yesafili™️ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea®️ 2 mg, advancing access to life-changing medicines for patients around the world.”
Supplies to Europe from this line are expected to begin from Q2FY27.
The block deal witnessed strong participation from domestic and foreign institutional investors. ICICI Prudential Mutual Fund emerged as the largest buyer, acquiring 3.69 crore shares (2.26% stake). HDFC Mutual Fund and Kotak Mahindra Mutual Fund each purchased 1.16 crore shares (0.71% stake), while SBI Mutual Fund acquired 50 lakh shares (0.31% stake). ICICI Prudential Life Insurance bought 25 lakh shares (0.15% stake). Aditya Birla Sun Life Mutual Fund, Franklin Templeton Mutual Fund and Mirae Asset Mutual Fund acquired 18.75 lakh shares (0.12% stake) each, while Tata Mutual Fund purchased 6.26 lakh shares (0.04% stake).
Other investors, including Axis Mutual Fund, UTI Mutual Fund, Mahindra Mutual Fund, IDFC Mutual Fund, HDFC Life Insurance, Bajaj Life Insurance, Norges Bank, Goldman Sachs Bank Europe, Morgan Stanley Asia Singapore, Societe Generale, Vanguard Emerging Markets Shares Index Fund, WhiteOak Capital Mutual Fund, Authum Investment & Infrastructure, Abakkus Growth Fund, Canara Robeco Mutual Fund and Eastspring Investments Asian Low Volatility Equity Fund, each acquired 6.26 lakh shares (0.04% stake). Citigroup Global Markets Singapore and BNP Paribas Arbitrage purchased 7.50 lakh shares (0.05% stake) each.
Mylan's relationship with Biocon began in 2009, when the companies entered into a global collaboration to develop and commercialise biosimilars. The partnership later expanded to generic insulin analogues. Mylan became a shareholder in Biocon in January 2026 after the company issued shares as part of the acquisition of Viatris' stake in Biocon Biologics. The latest transaction marks Mylan's complete exit from Biocon.
As of 30 June 2026, Biocon's promoters held a 44.67% stake in the company, while Mylan owned 5.64%.
Biocon is a global biopharmaceutical company focused on developing affordable therapies for chronic diseases, including diabetes, cancer and autoimmune disorders.
On a consolidated basis, the company's net profit declined 63.4% YoY to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations increased 2.26% YoY to Rs 4,517 crore during the quarter.
Shares of Biocon were down 0.70% at Rs 434.25 on the NSE.
According to media reports, U.S.-based Viatris-owned Mylan was looking to sell its entire 5.6% stake in the biotechnology company through block deals worth around Rs 3,481 crore. The transaction would mark Mylan's complete exit from Biocon after a 17-year partnership. The block deal was reportedly launched at a floor price of Rs 378.50 per share, a discount of 7.9% to Biocon's Monday closing price on the NSE.
Mylan partnered with Biocon in 2009 to develop and commercialise biosimilars, later expanding the alliance to generic insulin analogues. It became a Biocon shareholder in January 2026 after Biocon issued shares as part of the acquisition of Viatris' stake in Biocon Biologics. The latest block deal would bring Mylan's association with Biocon to an end.
As on June 2026, promoters held 44.67% stake in Biocon. Mylan Inc. held 5.64% in the company.
Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.
On a consolidated basis, the company's net profit declined 63.4% year-on-year to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations increased 2.26% YoY to Rs 4,517 crore during the quarter.
Biocon Ltd, Nuvoco Vistas Corporation Ltd, Container Corporation Of India Ltd and Cartrade Tech Ltd are among the other gainers in the BSE's 'A' group today, 14 July 2026.
Just Dial Ltd surged 14.16% to Rs 773.45 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 21.38 lakh shares were traded on the counter so far as against the average daily volumes of 56636 shares in the past one month.
Biocon Ltd soared 8.21% to Rs 444.25. The stock was the second biggest gainer in 'A' group. On the BSE, 476.03 lakh shares were traded on the counter so far as against the average daily volumes of 1.95 lakh shares in the past one month.
Nuvoco Vistas Corporation Ltd spiked 7.87% to Rs 340.55. The stock was the third biggest gainer in 'A' group. On the BSE, 9.13 lakh shares were traded on the counter so far as against the average daily volumes of 15124 shares in the past one month.
Container Corporation Of India Ltd exploded 4.93% to Rs 487.8. The stock was the fourth biggest gainer in 'A' group. On the BSE, 3.76 lakh shares were traded on the counter so far as against the average daily volumes of 1.26 lakh shares in the past one month.
Cartrade Tech Ltd advanced 4.75% to Rs 2933. The stock was the fifth biggest gainer in 'A' group. On the BSE, 60513 shares were traded on the counter so far as against the average daily volumes of 65547 shares in the past one month.
Nuvoco Vistas Corporation Ltd, Cipla Ltd, Aadhar Housing Finance Ltd, Alkem Laboratories Ltd are among the other stocks to see a surge in volumes on BSE today, 14 July 2026.
Biocon Ltd saw volume of 473.28 lakh shares by 10:46 IST on BSE, a 224.63 fold spurt over two-week average daily volume of 2.11 lakh shares. The stock increased 7.08% to Rs.439.60. Volumes stood at 5.05 lakh shares in the last session.
Nuvoco Vistas Corporation Ltd clocked volume of 8.72 lakh shares by 10:46 IST on BSE, a 56.34 times surge over two-week average daily volume of 15478 shares. The stock gained 7.81% to Rs.340.35. Volumes stood at 39713 shares in the last session.
Cipla Ltd notched up volume of 8.18 lakh shares by 10:46 IST on BSE, a 17.21 fold spurt over two-week average daily volume of 47526 shares. The stock rose 1.42% to Rs.1,447.00. Volumes stood at 20923 shares in the last session.
Aadhar Housing Finance Ltd notched up volume of 7.5 lakh shares by 10:46 IST on BSE, a 5.79 fold spurt over two-week average daily volume of 1.30 lakh shares. The stock slipped 2.50% to Rs.522.40. Volumes stood at 7.09 lakh shares in the last session.
Alkem Laboratories Ltd notched up volume of 1.9 lakh shares by 10:46 IST on BSE, a 5.3 fold spurt over two-week average daily volume of 35790 shares. The stock slipped 0.28% to Rs.5,559.15. Volumes stood at 39767 shares in the last session.
Biocon Ltd, SBI Cards & Payment Services Ltd, Cartrade Tech Ltd, IDBI Bank Ltd are among the other stocks to see a surge in volumes on NSE today, 14 July 2026.
Nuvoco Vistas Corporation Ltd saw volume of 184.57 lakh shares by 14:14 IST on NSE, a 67.12 fold spurt over two-week average daily volume of 2.75 lakh shares. The stock increased 8.02% to Rs.341.95. Volumes stood at 8.17 lakh shares in the last session.
Biocon Ltd recorded volume of 386.68 lakh shares by 14:14 IST on NSE, a 8.12 times surge over two-week average daily volume of 47.63 lakh shares. The stock gained 6.67% to Rs.438.35. Volumes stood at 75.05 lakh shares in the last session.
SBI Cards & Payment Services Ltd registered volume of 52.89 lakh shares by 14:14 IST on NSE, a 6.07 fold spurt over two-week average daily volume of 8.72 lakh shares. The stock rose 2.05% to Rs.631.40. Volumes stood at 10.02 lakh shares in the last session.
Cartrade Tech Ltd saw volume of 32.91 lakh shares by 14:14 IST on NSE, a 5.68 fold spurt over two-week average daily volume of 5.79 lakh shares. The stock increased 3.90% to Rs.2,908.50. Volumes stood at 5.8 lakh shares in the last session.
IDBI Bank Ltd witnessed volume of 461.8 lakh shares by 14:14 IST on NSE, a 4.54 times surge over two-week average daily volume of 101.82 lakh shares. The stock increased 3.76% to Rs.87.23. Volumes stood at 68.77 lakh shares in the last session.
Biocon announced that its long-standing partner, Duopharma Biotech Berhad (Duopharma Biotech) via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year.
As part of these contracts, Biocon's subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia.
The contracts comprise a three-year agreement valued at ~ MYR 155.27 million for human insulin, along with two 2-year agreements: ~ MYR 18 million for insulin glargine and ~ MYR 52.5 million for insulin aspart.
In line with policies indicated in the 13th Malaysia Plan (RMK-13) and the New Industrial Master Plan 2030 (NIMP 2030), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply.
The said contracts have been awarded to Duopharma (M) Sendirian Berhad, a wholly-owned subsidiary of Duopharma Biotech.
As part of these contracts, Biocon’s subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution.
The contracts comprise a three-year agreement valued at MYR 155.27 million for human insulin, along with two two-year agreements, which consists of MYR 18 million contract for insulin glargine and MYR 52.5 million contract for insulin aspart.
Shreehas Tambe, CEO & managing director, Biocon, said: “Malaysia has been central to Biocon’s insulin journey for over a decade, anchored by our integrated insulin manufacturing facility in the country – the largest in Asia.
Our Johor operations enable us to deliver insulin at scale, expanding patient access in Malaysia and around the world.”
The company had reported 63.4% drop in consolidated net profit to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations rose by 2.26% year-on-year (YoY) to Rs 4,517 crore during the period under review.
The scrip shed 0.17% to currently trade at Rs 422.65 on the BSE.